Kenvue Inc. (NYSE:KVUE) Shares Sold by ASB Consultores LLC

ASB Consultores LLC cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 29.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 13,988 shares of the company’s stock after selling 5,814 shares during the period. ASB Consultores LLC’s holdings in Kenvue were worth $254,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Manchester Capital Management LLC boosted its position in Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares during the last quarter. Mather Group LLC. purchased a new position in Kenvue in the first quarter valued at about $28,000. Riverview Trust Co acquired a new stake in Kenvue during the 1st quarter valued at approximately $33,000. MV Capital Management Inc. increased its holdings in Kenvue by 71.2% during the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after purchasing an additional 642 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the 1st quarter valued at approximately $33,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.02 on Friday. The company has a market cap of $44.08 billion, a PE ratio of 29.51, a P/E/G ratio of 2.92 and a beta of 1.40. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.55. The firm has a 50-day simple moving average of $20.92 and a 200 day simple moving average of $19.96. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. Kenvue’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 earnings per share. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, August 14th. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 annualized dividend and a yield of 3.56%. Kenvue’s dividend payout ratio (DPR) is currently 105.13%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on KVUE shares. UBS Group raised their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Wednesday, August 7th. Citigroup decreased their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Finally, JPMorgan Chase & Co. upped their price objective on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.44.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.